The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

Some of the biggest highlights from obesity studies in 2024 included new data on semaglutide and tirzepatide, as well as a new study on risks with sarcopenia. Image: Adobe Stock SURMOUNT-OSA ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

Dr. Altagrace Hanley, medical director at La Boussole Medical Spa & Wellness Center, has achieved board certification in obesity medicine. La Boussole's program includes advanced options such as GLP-1 ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Tirzepatide does not yield a significant increase in pancreatitis risk despite elevating pancreatic enzyme levels, according to study findings published in Obesity Science and Practice. Tirzepatide, a ...

GPs should not prescribe tirzepatide for weight loss until advised to do so by their local ICB, NHS England has said.

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

In this video, Jamy D. Ard, MD, FTOS, discusses treatment options, lifestyle interventions and strategies for patients with obesity.